Finnton Logo
AZN.LSE

AstraZeneca PLC

AZN.LSE, UK

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Crestor, Seloken, Lokelma, Roxadustat, Andexxa, Wainua, Symbicort, Fasenra, Pulmicort, Breztri/Trixeo, Saphnelo, Tezspire, Airsupra, Ultomiris, Soliris, Strensiq, Koselugo, Kanuma, Atacand, Plendil, Modip, Splendil, Munobal, Flodil, Komboglyze, Qtern, Byetta, XIGDUO, Accolate, Accoleit, Vanticon, Beyfortus, Synagis, FluMist, tixagevimab and cilgavimab, and sipavibart. It also provides Bricanyl Respules, Eklira Genuair/Tudorza/Bretaris, Bricanyl Turbuhaler, Rhinocort, Bevespi Aerosphere, Daliresp/Daxas, Oxis Turbuhaler, Breztri Aerosphere, Duaklir Genuair, Kavigale, Evusheld, Fluenz/FluMist, and Voydeya. The company offers its products for ocology, cardiovascular, renal and metabolism, respiratory & immunology, vaccines and immune, and therapies rare diseases. It serves primary and specialty care physicians through distributors and local representative offices in the United Kingdom, the United States, Europe, and Asia. It has a strategic agreement with Tempus to develop the largest multimodal foundation model in oncology. The company has a collaboration agreement with IonQ, Inc. for the development of quantum-accelerated computational chemistry workflow for healthcare, life sciences, and chemistry; a strategic research collaboration with CSPC Pharmaceutical Group Limited to advance the discovery and development of novel oral candidates, with the potential to treat diseases across multiple indications; and collaboration Revna Biosciences for lung cancer treatment. AstraZeneca PLC was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.

https://www.astrazeneca.com

Stock Price

GBp 0.00

0%

increase compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A

Is AstraZeneca (LSE:AZN) Still Sensibly Priced After A 31.3% One Year Share Gain - simplywall.st

1/17/2026

AZN.LSE
stock
AZN.LSE

Is AstraZeneca (LSE:AZN) Still Sensibly Priced After A 31.3% One Year Share Gain simplywall.st

Read more →

Assessing AstraZeneca (LSE:AZN) Valuation After Recent Share Price Softness And Ongoing Momentum - simplywall.st

1/13/2026

AZN.LSE
stock
AZN.LSE

Assessing AstraZeneca (LSE:AZN) Valuation After Recent Share Price Softness And Ongoing Momentum simplywall.st

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

BUY

$

Analyst Picks

Strong Buy

4

Buy

15

Hold

1

Sell

1

Strong Sell

0

Sentiment:

Bullish

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Earnings Ratio (P/E)

-

Medium

30.66

Low ≥ 50

High ≤ 10

Price to Book Ratio (P/B)

-

Very High

460.46

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Very Low

5.52 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Very Low

2.21 %

Low ≤ 2%

High ≥ 10%

Free Cash Flow - Revenue % (FCF)

-

Very High

29.28 %

Low ≤ 5%

High ≥ 15%

Debt to Equity

-

Very Low

1.49

Low ≥ 1

High ≤ 0.3

Investors

* Institutions hold a combined 0.00% of the total shares of AstraZeneca PLC

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

2025-12-31

EPS Estimate

2.13

Latest Release

Date

2025-09-30

EPS Actual

2.38

EPS Estimate

2.24

EPS Difference

0.14

Surprise Percent

6.25%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Potential Value Candidate(4)
Defensive
Moderately Defensive(6)
Dividend
Decent Dividend Payer(3.5)
Economic Moat
Wide Moat Company(7.3)
GARP
Fair GARP(3.5)
Growth
Weak Growth Prospect(3)
Momentum
Moderate Momentum(4.5)
Net Net
Not Undervalued (Net-Net)(2.5)
Quality
High Quality(7)
Value
Fair Value(4)

Income Statement

(Last Updated 2025-09-30)

Revenue

ÂŁ 0

Cost Of Revenue

ÂŁ 0

Gross Profit

ÂŁ 0

Operating Expenses

ÂŁ 0

Operating Income

ÂŁ 0

Interest Expense

ÂŁ 0

Pretax Income

ÂŁ 0

Net Income

ÂŁ 0

Income Tax Expense

ÂŁ 0

EBITDA

ÂŁ 0

Total Other Income Expense Net

ÂŁ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

ÂŁ 0

Short Term Investments

ÂŁ 0

Receivables

ÂŁ 0

Inventories

ÂŁ 0

Total Current Assets

ÂŁ 0

Property Plant Equipment

ÂŁ 0

Total Assets

ÂŁ 0

Payables

ÂŁ 0

Short Term Debt

ÂŁ 0

Long Term Debt

ÂŁ 0

Total Liabilities

ÂŁ 0

Equity

ÂŁ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

ÂŁ 0

Depreciation

ÂŁ 0

Change In Working Capital

ÂŁ 0

Cash From Operations

ÂŁ 0

Capital Expenditures

ÂŁ 0

Cash From Investing

ÂŁ 0

Cash From Financing

ÂŁ 0

Net Change In Cash

ÂŁ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.

Finnton Logo

Pricing

Contact us

Feedback

Privacy Policy

Terms of Service